Novartis AG
TREM2 STABILIZING ANTIBODIES
Last updated:
Abstract:
The present invention provides antibodies that bind to and stabilize human Triggering Receptor Expressed on Myeloid cells 2 (TREM2) protein and methods of using these antibodies.
Status:
Application
Type:
Utility
Filling date:
14 Oct 2019
Issue date:
7 May 2020